AIP
BMRN icon

Ahrens Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ahrens Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$8K – 252
2022
Q2 		$8K Hold
100
– – ﹤0.01% 681
2022
Q1 		$8K Sell
100
-100
-50% -$8.37K ﹤0.01% 766
2021
Q4 		$18K Buy
+200
New +$16.5K 0.01% 597

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Ahrens Investment Partners's BMRN Position: Q3 2022 in Review

Ahrens Investment Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 100 shares — an estimated $8K sold.

Ahrens Investment Partners first reported a position in BMRN in Q4 2021 and held it in 3 quarters. The position peaked at $18K in Q4 2021. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

  • Ahrens Investment Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Ahrens Investment Partners sold 100 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $8K.
  • Ahrens Investment Partners first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Ahrens Investment Partners's BioMarin Pharmaceuticals position peaked at $18K in Q4 2021.
  • 551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Ahrens Investment Partners's 13F filing for Q3 2022, filed 8 Nov 2022.